Compare MOV & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOV | AVXL |
|---|---|---|
| Founded | 1961 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.4M | 397.6M |
| IPO Year | 1993 | N/A |
| Metric | MOV | AVXL |
|---|---|---|
| Price | $21.70 | $4.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $31.50 | $22.00 |
| AVG Volume (30 Days) | 162.2K | ★ 4.1M |
| Earning Date | 11-25-2025 | 11-25-2025 |
| Dividend Yield | ★ 6.52% | N/A |
| EPS Growth | ★ 27.72 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | ★ $661,205,000.00 | N/A |
| Revenue This Year | $2.10 | N/A |
| Revenue Next Year | $0.24 | N/A |
| P/E Ratio | $22.13 | ★ N/A |
| Revenue Growth | ★ 2.78 | N/A |
| 52 Week Low | $12.85 | $2.86 |
| 52 Week High | $21.82 | $14.44 |
| Indicator | MOV | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 65.97 | 38.83 |
| Support Level | $20.39 | $3.66 |
| Resistance Level | $21.38 | $4.88 |
| Average True Range (ATR) | 0.66 | 0.42 |
| MACD | 0.06 | 0.19 |
| Stochastic Oscillator | 91.23 | 55.29 |
Movado Group Inc designs, develops, sources, markets, and distributes fine watches in the United States and internationally. It operates through the Watch and Accessory Brands and Company Stores segment. The Watch and Accessory Brands segment includes the designing, manufacturing, and distribution of watches and, to a lesser extent, jewelry and other accessories of quality owned brands and licensed brands. Its Company Stores segment includes the company's retail outlet locations in the United States and Canada. It generates maximum revenue from the Watch and Accessory Brands segment. Geographically, it derives the majority of its revenue from its international locations.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.